We are a clinical stage global biopharmaceutical company focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. Our first-in-class lead asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance fro…
ROIC dropped from -963.18% to -1554.80%, capital efficiency is deteriorating. Negative free cash flow of -$20M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$4M
▲ +91.0% YoY
Op. Margin
—
ROIC
-1868.30%
▼ -591.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$19M
▼ -18.9% YoY
Op. Cash Flow (TTM)
-$19M
▼ -20.2% YoY
Net Debt
-$8M
Net Cash Position
Cash & Equiv.
$8M
Continue Research